NASDAQ:ANTH - Anthera Pharmaceuticals Stock Price, Price Target & More

$0.34 0.00 (0.00 %)
(As of 04/23/2018 07:00 AM ET)
Previous Close$0.34
Today's Range$0.33 - $0.35
52-Week Range$0.30 - $3.36
Volume1.69 million shs
Average Volume2.59 million shs
Market Capitalization$7.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78

About Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals logoAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANTH
CUSIPN/A
Phone510-856-5600

Debt

Debt-to-Equity RatioN/A
Current Ratio0.68%
Quick Ratio0.68%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$140,000.00
Price / Sales56.83
Cash FlowN/A
Price / CashN/A
Book Value($0.42) per share
Price / Book-0.81

Profitability

EPS (Most Recent Fiscal Year)($3.75)
Net Income$-26,870,000.00
Net MarginsN/A
Return on Equity-18,164.04%
Return on Assets-286.30%

Miscellaneous

Employees21
Outstanding Shares23,400,000

How to Become a New Pot Stock Millionaire

Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Anthera Pharmaceuticals's stock reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals (NASDAQ:ANTH) issued its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. View Anthera Pharmaceuticals' Earnings History.

When is Anthera Pharmaceuticals' next earnings date?

Anthera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Anthera Pharmaceuticals.

What price target have analysts set for ANTH?

4 brokerages have issued 1 year target prices for Anthera Pharmaceuticals' shares. Their predictions range from $0.50 to $10.00. On average, they expect Anthera Pharmaceuticals' stock price to reach $4.50 in the next year. View Analyst Ratings for Anthera Pharmaceuticals.

Are investors shorting Anthera Pharmaceuticals?

Anthera Pharmaceuticals saw a increase in short interest in March. As of March 29th, there was short interest totalling 1,472,163 shares, an increase of 39.0% from the March 15th total of 1,058,839 shares. Based on an average daily trading volume, of 2,876,601 shares, the short-interest ratio is presently 0.5 days. Approximately 6.4% of the company's shares are sold short.

Who are some of Anthera Pharmaceuticals' key competitors?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul F. Truex, Exec. Chairman (Age 49)
  • Mr. John Craig Thompson, Pres, CEO & Director (Age 51)
  • Dr. Renee Martin Ph.D., Sr. VP of Medical Sciences (Age 49)
  • Dr. William R. Shanahan Jr., M.D., J.D., Chief Medical Officer & Sr. VP (Age 69)
  • Ms. May Liu, Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer (Age 42)

Has Anthera Pharmaceuticals been receiving favorable news coverage?

Media coverage about ANTH stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.22 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Anthera Pharmaceuticals' major shareholders?

Anthera Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include 683 CAPITAL MANAGEMENT, LLC Total Shares: 1,440,000 (6.70%). Company insiders that own Anthera Pharmaceuticals stock include John Craig Thompson and Paul F Truex. View Institutional Ownership Trends for Anthera Pharmaceuticals.

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of ANTH stock can currently be purchased for approximately $0.34.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $7.83 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-26,870,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Anthera Pharmaceuticals employs 21 workers across the globe.

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.


MarketBeat Community Rating for Anthera Pharmaceuticals (ANTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anthera Pharmaceuticals (NASDAQ:ANTH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Anthera Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 1,223.53%. The high price target for ANTH is $10.00 and the low price target for ANTH is $0.50. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.252.252.502.40
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$2.3750$5.8875
Price Target Upside: 1,223.53% upside883.39% upside79.92% upside346.02% upside

Anthera Pharmaceuticals (NASDAQ:ANTH) Consensus Price Target History

Price Target History for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ:ANTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018Jefferies GroupReiterated RatingHold$0.50MediumView Rating Details
3/12/2018Piper JaffrayDowngradeOverweight -> UnderweightN/AView Rating Details
3/6/2018HC WainwrightReiterated RatingBuyHighView Rating Details
2/21/2018Roth CapitalInitiated CoverageBuy -> Buy$10.00 -> $10.00HighView Rating Details
12/29/2016CitigroupDowngradeBuy -> NeutralN/AView Rating Details
12/28/2016SunTrust BanksDowngradeBuy -> Hold$48.00 -> $8.00N/AView Rating Details
6/20/2016FBR & CoReiterated RatingHoldN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings History and Estimates Chart

Earnings by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ:ANTH) Earnings Estimates

2018 EPS Consensus Estimate: ($1.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.34)($0.23)($0.29)
Q2 20182($0.27)($0.23)($0.25)
Q3 20182($0.34)($0.23)($0.29)
Q4 20182($0.40)($0.22)($0.31)

Anthera Pharmaceuticals (NASDAQ ANTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.53)N/AView Earnings Details
3/5/2018Q4 2017($0.82)($0.73)ViewN/AView Earnings Details
11/6/2017Q3 2017($0.90)($0.58)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.09)$0.03ViewN/AView Earnings Details
5/10/2017Q1 2017($1.4730)($2.03)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.2480)($2.88)$0.10 millionViewN/AView Earnings Details
11/4/2016Q3($3.04)($4.88)$0.18 millionViewN/AView Earnings Details
8/9/2016Q2($2.48)($2.80)$0.15 millionViewN/AView Earnings Details
5/9/2016Q1($2.24)($2.32)$0.15 millionViewN/AView Earnings Details
3/10/2016Q4($2.24)($1.44)$0.31 million$1.92 millionViewN/AView Earnings Details
11/6/2015Q315($2.08)($2.32)$0.31 million$0.73 millionViewN/AView Earnings Details
8/10/2015Q2($2.24)($2.00)$0.29 millionViewN/AView Earnings Details
5/11/2015Q115($2.48)($2.24)$0.25 millionViewN/AView Earnings Details
3/16/2015Q4 2014($2.64)($2.56)ViewN/AView Earnings Details
11/14/2014Q3 2014($2.88)($2.48)ViewN/AView Earnings Details
7/28/2014Q2 2014($3.92)($2.72)ViewN/AView Earnings Details
5/13/2014Q114($4.48)($3.12)ViewN/AView Earnings Details
3/12/2014($3.76)($3.84)ViewN/AView Earnings Details
10/29/2013Q3 2013($5.20)($2.40)ViewN/AView Earnings Details
7/30/2013Q2 2013($4.80)($3.28)ViewN/AView Earnings Details
5/13/2013Q1 2013($4.48)($3.84)ViewN/AView Earnings Details
3/26/2013Q412($1.20)($0.88)ViewN/AView Earnings Details
10/24/2012Q3 2012($10.24)($10.88)ViewN/AView Earnings Details
8/7/2012Q2 2012($22.40)($27.39)ViewN/AView Earnings Details
5/3/2012Q1 2012($35.20)($32.64)ViewN/AView Earnings Details
2/21/2012Q4 2011($38.40)($45.63)ViewN/AView Earnings Details
11/1/2011Q3 2011($34.56)($38.34)ViewN/AView Earnings Details
7/29/2011Q2 2011($33.92)($42.50)ViewN/AView Earnings Details
5/3/2011Q1 2011($23.68)($36.10)ViewN/AView Earnings Details
2/23/2011Q4 2010($19.84)($25.41)ViewN/AView Earnings Details
11/2/2010Q3 2010($30.08)($23.23)ViewN/AView Earnings Details
8/4/2010Q2 2010($16.00)($22.85)ViewN/AView Earnings Details
5/6/2010Q1 2010($12.80)($53.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Anthera Pharmaceuticals (NASDAQ:ANTH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.08%
Institutional Ownership Percentage: 16.65%
Insider Trading History for Anthera Pharmaceuticals (NASDAQ:ANTH)
Institutional Ownership by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Anthera Pharmaceuticals (NASDAQ ANTH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2017John Craig ThompsonCEOBuy8,550$1.32$11,286.0019,848View SEC Filing  
9/7/2017John Craig ThompsonCEOBuy10,400$1.43$14,872.0011,298View SEC Filing  
9/7/2017Paul F TruexDirectorBuy5,000$1.34$6,700.00View SEC Filing  
11/13/2015Colin HislopinsiderSell12,500$5.31$66,375.0019,147View SEC Filing  
11/11/2015Colin HislopInsiderSell5,000$5.38$26,900.0019,147View SEC Filing  
10/12/2015Debra OdinkCTOSell1,205$6.15$7,410.757,896View SEC Filing  
6/24/2013David E ThompsonDirectorBuy12,500$0.53$6,625.00View SEC Filing  
5/31/2013Bogdan DziurzynskiDirectorBuy1,250$0.59$737.50View SEC Filing  
1/30/2013Orbimed Advisors LlcDirectorBuy712,500$0.66$470,250.00View SEC Filing  
1/25/2013Orbimed Advisors LlcDirectorBuy220,250$0.65$143,162.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anthera Pharmaceuticals (NASDAQ ANTH) News Headlines

Source:
DateHeadline
-$0.60 Earnings Per Share Expected for Anthera Pharmaceuticals Inc (ANTH) This Quarter-$0.60 Earnings Per Share Expected for Anthera Pharmaceuticals Inc (ANTH) This Quarter
www.americanbankingnews.com - April 18 at 9:22 AM
Short Interest in Anthera Pharmaceuticals Inc (ANTH) Expands By 39.0%Short Interest in Anthera Pharmaceuticals Inc (ANTH) Expands By 39.0%
www.americanbankingnews.com - April 14 at 2:29 AM
Anthera Pharmaceuticals Inc (ANTH) Receives Average Recommendation of "Hold" from BrokeragesAnthera Pharmaceuticals Inc (ANTH) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 9:52 AM
Breakeven On The Horizon For Anthera Pharmaceuticals Inc (NASDAQ:ANTH)Breakeven On The Horizon For Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
finance.yahoo.com - April 10 at 5:30 PM
 Brokerages Expect Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.47 Per Share Brokerages Expect Anthera Pharmaceuticals Inc (ANTH) Will Announce Earnings of -$0.47 Per Share
www.americanbankingnews.com - April 1 at 9:14 AM
Anthera Pharmaceuticals (ANTH) Upgraded at ValuEngineAnthera Pharmaceuticals (ANTH) Upgraded at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM
Anthera Pharmaceuticals Inc (ANTH) Short Interest UpdateAnthera Pharmaceuticals Inc (ANTH) Short Interest Update
www.americanbankingnews.com - March 29 at 3:12 AM
Did Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH) Recent Earnings Growth Beat The Trend?Did Anthera Pharmaceuticals Inc’s (NASDAQ:ANTH) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - March 23 at 5:43 PM
Anthera Pharmaceuticals Inc (ANTH) Given Average Recommendation of "Hold" by AnalystsAnthera Pharmaceuticals Inc (ANTH) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 18 at 9:57 AM
Anthera Pharmaceuticals (ANTH) Stock Rating Reaffirmed by Jefferies GroupAnthera Pharmaceuticals (ANTH) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - March 17 at 9:24 PM
Anthera Fails Phase 3 Study, Time To Avoid - Seeking AlphaAnthera Fails Phase 3 Study, Time To Avoid - Seeking Alpha
seekingalpha.com - March 16 at 8:19 AM
Anthera Pharmaceuticals (ANTH) & NuCana (NCNA) Head-To-Head SurveyAnthera Pharmaceuticals (ANTH) & NuCana (NCNA) Head-To-Head Survey
www.americanbankingnews.com - March 16 at 5:22 AM
Anthera Pharmaceuticals Inc to Post Q3 2018 Earnings of ($0.34) Per Share, Jefferies Group Forecasts (ANTH)Anthera Pharmaceuticals Inc to Post Q3 2018 Earnings of ($0.34) Per Share, Jefferies Group Forecasts (ANTH)
www.americanbankingnews.com - March 14 at 8:51 AM
Anthera to explore options after lead drug fails trial, shares slumpAnthera to explore options after lead drug fails trial, shares slump
www.reuters.com - March 13 at 7:17 PM
Is Anthera Dead in the Water?Is Anthera Dead in the Water?
www.msn.com - March 13 at 7:17 PM
Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - SlideshowAnthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow
seekingalpha.com - March 13 at 7:17 PM
Anthera Pharmaceuticals stock plunges toward record low after failed drug trial - MarketWatchAnthera Pharmaceuticals' stock plunges toward record low after failed drug trial - MarketWatch
www.marketwatch.com - March 12 at 6:40 PM
Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge - BenzingaMid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge - Benzinga
www.benzinga.com - March 12 at 6:40 PM
Piper Jaffray Companies Downgrades Anthera Pharmaceuticals (ANTH) to UnderweightPiper Jaffray Companies Downgrades Anthera Pharmaceuticals (ANTH) to Underweight
www.americanbankingnews.com - March 12 at 12:53 PM
Anthera Pharma (ANTH) Phase 3 Clinical Study of Sollpura Did Not Meet Primary EndpointAnthera Pharma (ANTH) Phase 3 Clinical Study of Sollpura Did Not Meet Primary Endpoint
www.streetinsider.com - March 12 at 9:01 AM
Anthera to explore options after lead drugs trial failureAnthera to explore options after lead drug's trial failure
www.cnbc.com - March 12 at 9:01 AM
Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of SollpuraAnthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
finance.yahoo.com - March 12 at 9:01 AM
Anthera Pharmaceuticals stock plunges toward record low after failed drug trialAnthera Pharmaceuticals' stock plunges toward record low after failed drug trial
finance.yahoo.com - March 12 at 9:01 AM
SunTrust Banks Research Analysts Lift Earnings Estimates for Anthera Pharmaceuticals Inc (ANTH)SunTrust Banks Research Analysts Lift Earnings Estimates for Anthera Pharmaceuticals Inc (ANTH)
www.americanbankingnews.com - March 12 at 2:48 AM
Pig out: How an East Bay drug maker is betting on porcine-less disruption of cystic fibrosis - San Francisco Business TimesPig out: How an East Bay drug maker is betting on porcine-less disruption of cystic fibrosis - San Francisco Business Times
www.bizjournals.com - March 8 at 8:23 AM
Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference - GlobeNewswire (press release)Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 8 at 8:23 AM
Analysts Set Expectations for Anthera Pharmaceuticals Incs Q1 2018 Earnings (ANTH)Analysts Set Expectations for Anthera Pharmaceuticals Inc's Q1 2018 Earnings (ANTH)
www.americanbankingnews.com - March 8 at 6:40 AM
Anthera Pharma (ANTH) Says its Compliant with Nasdaq Listing CriteriaAnthera Pharma (ANTH) Says it's Compliant with Nasdaq Listing Criteria
www.streetinsider.com - March 7 at 6:35 PM
BRIEF-Anthera Pharma Files For Mixed Shelf Of Up To $100 MillionBRIEF-Anthera Pharma Files For Mixed Shelf Of Up To $100 Million
www.reuters.com - March 7 at 6:35 PM
Anthera Pharmaceuticals to Present at the 30TH Annual ROTH ConferenceAnthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference
finance.yahoo.com - March 7 at 6:35 PM
Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria - GlobeNewswire (press release)Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:17 AM
Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing CriteriaAnthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria
finance.yahoo.com - March 6 at 5:41 PM
Anthera Pharmaceuticals (ANTH) Receives Buy Rating from HC WainwrightAnthera Pharmaceuticals (ANTH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 6 at 3:28 PM
Anthera Pharmaceuticals (ANTH) Posts  Earnings ResultsAnthera Pharmaceuticals (ANTH) Posts Earnings Results
www.americanbankingnews.com - March 6 at 8:31 AM
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results - GlobeNewswire (press release)Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:15 AM
Anthera Pharmaceuticals (ANTH) Downgraded by Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - February 28 at 5:50 PM
Anthera Pharmaceuticals (ANTH) Raised to Buy at Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - February 27 at 5:10 PM
Implied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock Options - NasdaqImplied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock Options - Nasdaq
www.nasdaq.com - February 27 at 8:18 AM
Implied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock OptionsImplied Volatility Surging for Anthera Pharmaceuticals (ANTH) Stock Options
finance.yahoo.com - February 26 at 5:45 PM
-$0.71 EPS Expected for Anthera Pharmaceuticals Inc (ANTH) This Quarter-$0.71 EPS Expected for Anthera Pharmaceuticals Inc (ANTH) This Quarter
www.americanbankingnews.com - February 26 at 10:48 AM
Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics - PR Newswire (press release)
www.prnewswire.com - February 23 at 8:21 AM
Anthera Pharmaceuticals (ANTH) Research Coverage Started at Roth CapitalAnthera Pharmaceuticals (ANTH) Research Coverage Started at Roth Capital
www.americanbankingnews.com - February 21 at 11:46 PM
Zacks Investment Research Downgrades Anthera Pharmaceuticals (ANTH) to HoldZacks Investment Research Downgrades Anthera Pharmaceuticals (ANTH) to Hold
www.americanbankingnews.com - February 21 at 4:58 PM
Anthera Pharmaceuticals (ANTH) Upgraded by Zacks Investment Research to "Buy"Anthera Pharmaceuticals (ANTH) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - February 20 at 5:08 PM
Anthera Pharmaceuticals (ANTH) Set to Announce Earnings on MondayAnthera Pharmaceuticals (ANTH) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 19 at 3:46 AM
Research Analysts Offer Predictions for Anthera Pharmaceuticals Incs Q1 2018 Earnings (ANTH)Research Analysts Offer Predictions for Anthera Pharmaceuticals Inc's Q1 2018 Earnings (ANTH)
www.americanbankingnews.com - February 19 at 3:16 AM
Research Analysts Set Expectations for Anthera Pharmaceuticals Incs FY2022 Earnings (ANTH)Research Analysts Set Expectations for Anthera Pharmaceuticals Inc's FY2022 Earnings (ANTH)
www.americanbankingnews.com - February 16 at 4:32 PM
FY2019 EPS Estimates for Anthera Pharmaceuticals Inc Raised by Analyst (ANTH)FY2019 EPS Estimates for Anthera Pharmaceuticals Inc Raised by Analyst (ANTH)
www.americanbankingnews.com - February 15 at 3:10 PM
Anthera Pharmaceuticals (ANTH) Rating Lowered to Hold at Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 14 at 4:20 PM
Anthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment ResearchAnthera Pharmaceuticals (ANTH) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 13 at 5:54 PM

SEC Filings

Anthera Pharmaceuticals (NASDAQ:ANTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anthera Pharmaceuticals (NASDAQ:ANTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anthera Pharmaceuticals (NASDAQ ANTH) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.